Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer
Patients with advanced prostate cancer usually receive some kind of pharmaceutical castration or undergo surgical castration. At the investigators department the pharmaceutical treatment is most often given with a 3 month interval.
Over the last few years new drugs, which allow for lees frequent treatment, have been developed. The purpose of this study is to assess how the treatment affects patients and if our current patients would prefer to receive treatment at different intervals than they do at the present time. At the same time the investigators will assess how surgical treatment affects our patients. This will be assessed by patient questionnaires administered at our clinic.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Herlev, Danemark, 2730
- Department of Urology, Herlev Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- A diagnosis of advanced prostate cancer
- Receiving hormone manipulation treatment (pharmaceutical castration) OR having undergone surgical castration (orchiectomy)
Exclusion Criteria:
- Inability to read/write Danish
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Pharmaceutical group
Patients in pharmaceutical castration treatment for advanced prostate cancer
|
|
Surgical group
Patients having undergone surgical castration treatment for advanced prostate cancer
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Preferred treatment/control frequency for patients with advanced prostate cancer
Délai: Up to 1 year
|
Preferred treatment frequency is assessed by patient answers to the question: "If treatments were equally effective from a medical standpoint - How often would you then prefer to receive treatment" |
Up to 1 year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Treatment satisfaction
Délai: Up to 1 year
|
Treatment satisfaction ranging from "Very satisfied" til "Very unsatisfied" assessed by patient answers to the questionnaire
|
Up to 1 year
|
|
Side effects to treatment
Délai: Up to 1 year
|
Side effects to treatment assessed by patient answers to the questionnaire
|
Up to 1 year
|
|
Treatment satisfaction, preferred frequency of clinical control, and side effects after surgical castration
Délai: Up to 1 year
|
As a secondary endpoint the investigators will look at answers to satisfaction, wishes for control visits and side effects in the group of patients who received surgical castration for their advanced prostate cancer.
|
Up to 1 year
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Mikkel Fode, MD, Herlev Hospital, University of Copenhagen
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- HeH.750.19-25
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .